The review found no eligible studies for this question.
Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeksThomsen 1998 compared with mesalamine (moderate certainty).
Budesonide 9 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI < 150) compared with mesalamine (moderate certainty).
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).
Budesonide 9 mg probably leads to lower withdrawal due to disease worsening compared with mesalamine (moderate certainty).
Budesonide probably leads to lower clinical remission (ITT analysis) compared with mesalamine (moderate certainty).
Budesonide probably leads to lower endoscopic improvement Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).
Budesonide probably leads to lower histologic remission Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in remission (combined clinical and endoscopic remission) compared with mesalamine (low certainty).
Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).
It is very uncertain whether budesonide 6 mg changes continued remission at 12 months compared with mesalamine 3 g (very low certainty).